US Regulators Clear Remdesivir for COVID-19 Outpatient Use

Some patients seeking treatment outside hospitals can now use the antiviral remdesivir after U.S. drug regulators late Friday expanded approval of the drug.

The Food and Drug Administration (FDA) said the expansion was supported by a study run by Gilead Sciences, which developed remdesivir, showing the drug cut the risk of hospitalization by 87 percent among people who tested positive for COVID-19.

No other research was cited by the FDA.

The study was done before the Omicron variant of the CCP (Chinese Communist Party) virus became dominant in the United States, though the National Institutes of Health-convened COVID-19 Treatment Guidelines Panel said recently (pdf) the drug “is expected to be active against the Omicron” strain.

The panel recommended remdesivir be made an option for non-hospitalized patients alongside the already-available monoclonal antibody treatment sotrovimab from GlaxoSmithKline.

Monoclonal antibodies require a one-time intravenous infusion, versus IV administration across three straight days for remdesivir.

Dr. David Boulware, an infectious diseases specialist at the University of Minnesota who studies COVID-19 treatments, said in a social media post that the Gilead study was small—562 people were enrolled, about half of whom received a placebo—and that a followup randomized controlled study would likely find a lower effectiveness against hospitalization.

Remdesivir also did not reduce the viral virus load in patients, unlike COVID-19 pills from Pfizer and Merck, two other treatment options, he noted.

The FDA’s move means individuals 12 or older who weigh at least 88 pounds, have tested positive for COVID-19, are not hospitalized, and are deemed at high risk for progression to severe COVID-19 can now get the drug, which was previously restricted to hospitalized patients.

The FDA also authorized the drug for children younger than 12 who weigh at least 3.5 kilograms (7.7 pounds) and meet the same criteria.

“Today’s actions provide adults and pediatric patients, with mild-to-moderate COVID-19 who are at high risk of severe COVID-19, with a treatment option they could receive outside of a traditional inpatient hospital setting, including at skilled nursing facilities, home healthcare settings and outpatient facilities such as infusion centers,” Dr. Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a statement.

The expanded clearance “provides FDA imprimatur on what is already happening to fill in the supply limitations of other therapeutics. So, it is a good thing,” Dr. David Wohl, a professor at the University of Carolina at Chapel Hill’s Institute of Global Health and Infectious Diseases, told The Epoch Times in an email.

Wohl, who has received funding from Gilead, has studied remdesivir and found it helped prevent death.

Additional studies have also shown “remdesivir is also effective in the early stages of COVID-19 infection, in addition to helping patients who are hospitalized with the disease,” Gilead CEO Daniel O’Day said in a press release.

On the other hand, some research on remdesivir, the earliest drug approved against COVID-19 in the United States, has found mixed results. For instance, a study published in The Lancet last year found no clinical benefit among severely ill patients who were admitted to hospitals.

Additionally, several studies have concluded kidney disorders are one of the side effects from the drugs and remdesivir’s label (pdf) says that kidney problems were observed in testing on animals.

People who are planning to get the drug, also known as Veklury, should tell their healthcare provider if they have kidney or liver problems before receiving it, according to the label.


Zachary Stieber covers U.S. news and stories relating to the COVID-19 pandemic. He is based in Maryland.

Source link

One thought on “US Regulators Clear Remdesivir for COVID-19 Outpatient Use”

  1. Lisa says:

    This drug most definitely causes kidney (and liver) damage. And many deaths and severe damage was demonstrated in the initial research in Africa. Early on when patients developed pulmonary edema it was confused (and still is) with the effects of this virus, but is actually pulmonary edema secondary to kidney failure. The antiviral effects of this drug (with unacceptably high risk) is very miniscule compared to safe and effective therapies as detailed by FLCCC Alliance.

Leave a Reply

Your email address will not be published.


join the Patriot Network

Meet with other patriots

No censorship. Be free.